M&A Deal Summary |
|
---|---|
Date | 2021-05-03 |
Target | Myriad Autoimmune s Vectra Testing Business |
Sector | Test/Measurement Equipment |
Buyer(s) | LabCorp |
Sellers(s) | Myriad |
Deal Type | Divestiture |
Deal Value | 150M USD |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Sector | Test/Measurement Equipment |
Employees | 67,000 |
Revenue | 12.2B USD (2023) |
LabCorp of America Holdings is a provider of medical laboratory tests and services through a national network of primary clinical laboratories and specialty testing laboratories. LabCorp is based in Burlington, North Carolina.
DEAL STATS | # |
---|---|
Overall | 37 of 44 |
Sector (Test/Measurement Equipment) | 5 of 5 |
Type (Divestiture) | 12 of 15 |
State (Utah) | 3 of 3 |
Country (United States) | 35 of 42 |
Year (2021) | 1 of 4 |
Size (of disclosed) | 12 of 14 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2019-10-22 |
South Bend Medical Foundation - Diagnostic Clinical Laboratory Assets
Indiana, United States South Bend Medical Foundation - Diagnostic Clinical Laboratory Assets provides laboratory testing services and integrates pathology services to customers in the region. |
Buy | - |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2021-05-20 |
Covance
Princeton, New Jersey, United States Covance is a drug development company and a provider in nutritional analysis, is dedicated to advancing healthcare and delivering Solutions Made Real. Covance was founded in 1987 and is based in Princeton, New Jersey. |
Sell | - |
Category | Company |
---|---|
Founded | 1991 |
Sector | Life Science |
Employees | 2,700 |
Revenue | 753M USD (2023) |
Myriad is a molecular diagnostic company discovers and commercialize a transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad was founded in 1991 and is based in Salt Lake City, Utah.
DEAL STATS | # |
---|---|
Overall | 3 of 4 |
Sector (Test/Measurement Equipment) | 1 of 1 |
Type (Divestiture) | 3 of 4 |
State (Utah) | 3 of 3 |
Country (United States) | 3 of 4 |
Year (2021) | 3 of 4 |
Size (of disclosed) | 1 of 3 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2021-04-27 |
Myriad myPath Melanoma
Salt Lake City, Utah, United States Myriad myPath Melanoma is a clinically validated GEP test designed to be used as an adjunct to histopathology when the distinction between a benign nevus and a malignant melanoma cannot be made confidently by histopathology alone. |
Sell | $33M |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2021-05-24 |
Myriad RBM
Austin, Texas, United States Myriad RBM is a multiplexed immunoassay testing laboratory that solves complex drug development challenges with innovative biomarker services and a novel whole blood immunophenotyping device (TruCulture®). Myriad RBM was founded in 2002 and is based in Austin, Texas. |
Sell | - |